ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

December 5, 2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

December 5, 2019

Teva Pharmaceuticals announced that it will re-introduce vincristine, a cancer drug used in adult cancers and of special importance to pediatric oncology, to the market.

According to a statement from Teva, there was no indication of a possible shortage when the company removed vincristine from the market earlier this year. However, given the lifesaving potential of the drug and since there is no reliable single supply anticipated in the near term, Teva will re-introduce vincristine and plans to manufacture it at the company’s plant in the United States (U.S.).

December 5, 2019

ASCO is inviting the entire cancer community to support I Live to Conquer Cancer by watching and sharing videos featuring their colleagues and by using the ACT Network to ask Congress to make it possible for every patient to access high-quality cancer care

December 3, 2019

A new study in the Journal of Oncology Practice (JOP) examines the factors contributing to low enrollment on prostate clinical trials.  The findings suggest that a more accurate accrual rate calculation is needed. The study also finds that there is room to examine and improve patient and physician interactions around clinical trials. 

November 26, 2019

The American Society of Clinical Oncology (ASCO) released today a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality, high-value care. The updated model reflects lessons learned from previous demonstration programs, including a PCOP pilot in New Mexico.  

November 22, 2019

During the American Medical Association (AMA) House of Delegates (HOD) interim meeting this month, delegates approved several ASCO-backed resolutions and incorporated them into the AMA’s advocacy agenda. The resolutions approved by the HOD include:

November 22, 2019

Congress passed another continuing resolution (CR) on November 21 – the second CR since the start of the fiscal year (FY) on October 1. The CR provides flat funding for government agencies through December 20 to avoid a government shutdown and gives Congress more time to come to an agreement on a final FY 2020 appropriations package.

Short-term spending bills make it difficult for the National Institutes of Health (NIH) – as well as the institutions and scientists it supports – to effectively plan for research projects.  

November 21, 2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

November 21, 2019

In January 2020, the American Society of Clinical Oncology (the Society) will launch the Association for Clinical Oncology (the Association), a 501(c)(6) professional association that will conduct expanded advocacy activities directed toward policymakers in support of high-quality patient care. Organizations with the 501(c)(6) tax-exemption have increased flexibility in how they can advocate for issues on behalf of their members—the reason many other medical specialty societies have adopted this structure.

November 15, 2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

November 15, 2019

ASCO's delegates to the American Medical Association’s (AMA) House of Delegates (HOD) will propose several resolutions during the policy-making body’s interim meeting, which will be held November 16-19, 2019. ASCO currently sends three delegates to the AMA HOD: Edward P. Balaban, DO, FACP, FASCO; Thomas A. Marsland, MD, FASCO; and Ray D. Page, DO, PhD, FACOI, FASCO. The society also has two alternate delegates to the HOD: Kristina L. Novick, MD and Steve Y. Lee, MD. ASCO’s Resident Fellow Section Delegate is Erin L. Schwab, MPH, BS, MD.

November 15, 2019

On December 11, from 3–4 PM (ET), the Oncology Nursing Society and ASCO will co-host a free webinar, “Offering Clinical Trials Can Make a Difference: Patient and Care Team Perspectives.”

November 14, 2019

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.

November 14, 2019

CancerLinQ LLC, a nonprofit subsidiary of ASCO, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives, are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.

November 13, 2019

The MEDS Act takes important steps toward ending the drug shortage crisis we are experiencing today, ASCO Board of Directors member Peter C. Adamson, MD stated during a briefing on Capitol Hill. Dr. Adamson spoke in support of Senate bill S. 2723, “The Mitigating Emergency Drug Shortages (MEDS) Act,” at the November 5 briefing.

Pages